Nexavar is quoted as dominating the liver cancer market, leaving just the small niche of liver resection to PI-88. I guess the people in the know could see this happening (and have already exited the stock). So we seem due for a major correction.
I may look to pick some up around $1.50, as this seems close to book value. But I am worried that Nexavar will move into PI-88's market. That could mean we drop even further.
They always say that risky biotechs are only for money you can afford to lose. It's a good principle to guide your investment strategy.
- Forums
- ASX - By Stock
- broker report says sell with valuation 1.50
Nexavar is quoted as dominating the liver cancer market, leaving...
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity